RATIONALE: Umbilical cord blood or placental blood transplantation may be able to replace immune cells that were destroyed by the chemotherapy or radiation therapy that was used to kill cancer cells.

PURPOSE: Phase II trial to study the effectiveness of umbilical cord blood and placental blood transplantation in treating patients who have hematologic cancer or aplastic anemia.

Condition	Treatment or Intervention	Phase
Langerhans cell histiocytosis childhood Hodgkin's lymphoma childhood non-Hodgkin's lymphoma hematopoietic and lymphoid cancer	Procedure: biological response modifier therapy  Procedure: bone marrow ablation with stem cell support  Procedure: umbilical cord blood transplantation	Phase II

Further Study Details: 

OBJECTIVES:

• Determine the response rate of patients with chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis, hereditary immunodeficiency, or storage disorder treated with allogeneic umbilical cord and placental blood transplantation.
• Determine the toxicity of this regimen in these patients.
• Determine survival in these patients treated with this regimen.
• Determine the incidence of graft-versus-host disease in these patients treated with this regimen.

OUTLINE: Patients receive a standard preparative regimen for their disease. Following the preparative regimen patients undergo umbilical cord blood stem cell transplantation on day 0.

Patients are followed every 1-2 weeks for 6 months.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study within 4-5 years.

Ages Eligible for Study:  up to  60 Years,  Genders Eligible for Study:  Both

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of chronic myeloid leukemia, acute leukemia, lymphoma, myeloma, myelodysplasia, aplastic anemia, Fanconi's anemia, histiocytosis, hereditary immunodeficiency, or storage disorder
• Eligible for allogeneic bone marrow transplantation, but lacking a donor
• Available donor umbilical cord blood that is mismatched on no more than 2 HLA loci
• HIV negative
• Hepatitis B surface antigen and hepatitis C negative

PATIENT CHARACTERISTICS: Age:

• Under physiologic 60

Performance status:

• Not specified

Life expectancy:

• Not specified

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2 times normal
• No severe hepatic disease
• Hepatitis B surface antigen and hepatitis C negative

Renal:

• Creatinine less than 2 times normal

Other:

• HIV negative
• Not pregnant or nursing
• No other serious medical or psychiatric illness that would preclude study compliance
• No serious infection

PRIOR CONCURRENT THERAPY: Biologic therapy

• Not specified

Chemotherapy

• Not specified

Endocrine therapy

• Not specified

Radiotherapy

• Not specified

Surgery

• Not specified

New York
      Herbert Irving Comprehensive Cancer Center at Columbia University, New York,  New York,  10032,  United States; Recruiting

Study chairs or principal investigators

David G. Savage, MD,  Study Chair,  Herbert Irving Comprehensive Cancer Center   

Study ID Numbers:  CDR0000068384; CPMC-IRB-7934; CPMC-CAMP-021; NCI-G00-1899; NCT00008164
Record last reviewed:  January 2001
Last Updated:  December 6, 2004
Record first received:  January 6, 2001
ClinicalTrials.gov Identifier:  NCT00008164
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08